Literature DB >> 9017355

Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin-dependent (type 1) diabetes mellitus at one-year follow-up.

O Schnell1, D Muhr, S Dresel, M Weiss, M Haslbeck, E Standl.   

Abstract

Diabetic neuropathy is thought to comprise a reversible metabolic and an irreversible structural component of neuronal abnormality. To investigate whether the cardiac sympathetic denervation recently described in newly diagnosed, but metabolically stabilized, diabetic patients without myocardial perfusion abnormalities reflects transient or permanent sympathetic abnormalities, 123-I-metaiodobenzylguanidine (123-I-MIBG) scintigraphy was performed in 16 patients with insulin-dependent (Type 1) diabetes mellitus (IDDM) 1 year after initial assessment and diagnosis. All patients had been treated with an intensified insulin therapy for 1 year. HbA1c had fallen from 11.5 +/- 2.0% to 6.3 +/- 0.9% (p < 0.001). The global myocardial 123-I-MIBG uptake (score 1-6) had improved in 7 patients at 1 year, remained unchanged in 7, and deteriorated in 2 patients. Regionally, the myocardial uptake score of the posterior and septal regions had improved significantly (p < 0.01, p = 0.02) with a mean uptake score in the groups of 3.8 +/- 1.1 and 3.4 +/- 1.2 at diagnosis versus 2.6 +/- 0.5 and 2.5 +/- 0.9 at 1 year. Myocardial uptake scores of the anterior, lateral, and apical regions had also improved in 7, 6, and 9 patients, but the mean changes of these scores did not reach significance. The study demonstrates that scintigraphically assessed cardiac sympathetic denervation in newly diagnosed, but metabolically stabilized, IDDM patients is partially reversed with improved metabolic control after 1 year of intensified insulin therapy. We suggest that even in the early stage of IDDM, cardiac sympathetic dysfunction is composed of reversible and irreversible neuronal abnormalities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9017355     DOI: 10.1002/(SICI)1096-9136(199701)14:1<57::AID-DIA297>3.0.CO;2-7

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability.

Authors:  Arthur J H A Scholte; Joanne D Schuijf; Victoria Delgado; Jurriaan A Kok; Mieke T J Bus; Arie C Maan; Marcel P Stokkel; Antje V Kharagitsingh; Petra Dibbets-Schneider; Ernst E van der Wall; Jeroen J Bax
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-22       Impact factor: 9.236

3.  Diabetic cardiomyopathy: ongoing controversies in 2012.

Authors:  P M Seferović; I Milinković; A D Ristić; J P Seferović Mitrović; K Lalić; A Jotić; V Kanjuh; N Lalić; B Maisch
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

Review 4.  [Autonomic disorders in polyneuropathies].

Authors:  M J Hilz; M Dütsch; B Neundörfer
Journal:  Med Klin (Munich)       Date:  1998-09-15

Review 5.  Type 1 diabetes and cardiovascular disease.

Authors:  Oliver Schnell; Francesco Cappuccio; Stefano Genovese; Eberhard Standl; Paul Valensi; Antonio Ceriello
Journal:  Cardiovasc Diabetol       Date:  2013-10-28       Impact factor: 9.951

6.  A Comparative Assessment of Cardiovascular Autonomic Reflex Testing and Cardiac 123I-Metaiodobenzylguanidine Imaging in Patients with Type 1 Diabetes Mellitus without Complications or Cardiovascular Risk Factors.

Authors:  Triantafyllos Didangelos; Efstratios Moralidis; Eleni Karlafti; Konstantinos Tziomalos; Charalambos Margaritidis; Zisis Kontoninas; Ioannis Stergiou; Maria Boulbou; Marianthi Papagianni; Emmanouel Papanastasiou; Apostolos I Hatzitolios
Journal:  Int J Endocrinol       Date:  2018-03-12       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.